Thromb Haemost 2007; 97(05): 722-729
DOI: 10.1160/TH07-01-0046
Theme Issue Article
Schattauer GmbH

Chemokines and thrombogenicity

Michele P. Lambert
1  Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
2  Department of Pediatrics
,
Bruce S. Sachais
3  Department of Pathology and Laboratory Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
,
M. Anna Kowalska
1  Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
4  Center for Medical Biology, Polish Academy of Science, Lodz, Poland
› Author Affiliations
Further Information

Publication History

Received 22 January 2007

Accepted after revision 01 March 2007

Publication Date:
24 November 2017 (online)

Summary

Thrombosis is an important clinical entity, and pathologic thrombosis, in the form of atherosclerosis, is a major cause of morbidity and mortality. Recent research points to the role of chemokines, normally key factors in inflammation, in thrombogenesis. Many recent studies in murine transgenic and knockout models show that chemokines and their receptors are important modulators of the process of thrombus formation, particularly in atherosclerosis. Platelet-released chemokines can potentiate or inhibit thrombosis and inflammation.This review focuses on the role of chemokines in platelet activation and thrombosis, particularly as it relates to atherosclerosis. Further studies to define this complex interaction are underway.